ScreenerHero

IVACC Intervacc AB (publ)

STO · SE · Healthcare · Biotechnology · intervacc.se
0.9350SEK-3.71%Mkt Cap: 30.48M $P/E: —

Intervacc AB (publ) develops novel veterinary vaccines for animals in Sweden. The company's product pipeline includes Strangvac, a vaccine against equine strangles for horses; INV274, antigens for a vaccine against strep…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap30.48M USD
Enterprise Value19.53M USD
Revenue (TTM)1.73M USD
Gross Profit-1.10M USD
Net Income (TTM)-7.73M USD
Revenue/Share0.05 SEK
Last Price0.9350 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.18
PEG—
EV/EBITDA-2.71
EV/Revenue11.27
P/S18.27
P/B1.42
EPS (TTM)-0.26
EPS (Forward)-0.82
52W Range
0.572041% of range1.462
52W High1.462 SEK
52W Low0.5720 SEK
Profitability
Gross Margin-57.18%
Oper. Margin-329.84%
EBITDA Margin0.00%
Profit Margin-402.32%
ROE-29.40%
ROA-27.45%
Growth
Revenue Growth-11.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.29M USD
CapEx (TTM)108.28K USD
FCF Margin-233.50%
FCF Yield-13.27%
Net Debt-12.13M USD
Net Debt/EBITDA1.68
Balance Sheet
Debt/Equity0.00
Current Ratio4.51
Quick Ratio4.15
Book Value/Sh0.68 SEK
Cash/Share0.38 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.000 SEK
Upside (mean)+113.9%
Target Range1.900 SEK – 2.100 SEK
1.900+113.9% to mean2.100
# Analysts2
Ownership
Shares Out.340.81M
Float197.61M
Insiders18.93%
Institutions32.81%
Technical
SMA 501.101 (-15.1%)
SMA 2001.044 (-10.5%)
Beta0.15
S&P 52W Chg14.58%
Avg Vol (30d)221.67K
Avg Vol (10d)293.59K
Technical Indicators
RSI (14)41.0
MACD-0.0321
MACD Signal-0.0397
MACD Hist.+0.0076
BB Upper1.063 SEK
BB Middle0.9989 SEK
BB Lower0.9347 SEK
BB Width12.84%
ATR (14)0.0580 SEK
Vol Ratio (20d)2.45x